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Background: The purpose of this study was to evaluate the release of chlorhexidine as an 
antifungal drug from doped self-cured poly (methyl methacrylate) (PMMA) acrylic resin and 
the effect of the drug released on the growth of Candida albicans.
Methods: Release of chlorhexidine was evaluated using liquid chromatography, and the effect 
of the drug on the growth of C. albicans was investigated microbiologically using a “well” 
technique on Saboraud culture medium inoculated with a resistant strain of C. albicans.
Results: Chlorhexidine leached steadily out of the acrylic resin into distilled water at mouth 
temperature, and the sustained drug release continued throughout the 28-day test period. The 
drug released also demonstrated antifungal activity against the resistant strain of C. albicans.
Conclusion: The findings of this study support the use of chlorhexidine-impregnated self-cured 
PMMA chair-side resin as a new dosage form for the treatment of denture-induced stomatitis.
Keywords: chlorhexidine, poly (methyl methacrylate), eluates, antifungal drug, denture 
  stomatitis, Candida albicans
Introduction
Candida-induced denture stomatitis is a common form of oral candidosis that manifests 
as diffuse inflammation of the denture-bearing areas. Oral candidosis appears to be 
caused by a multiplicity of predisposing factors.1–3 Adherence of Candida albicans 
has been implicated as the first step in the pathogenesis of oral candidosis,4 and its 
relative cell hydrophobicity is also a contributory factor.5
Chlorhexidine gluconate is widely prescribed as an antiseptic mouthwash in den-
tistry due to its broad-spectrum antimicrobial activity, including C.   albicans.6 The 
antifungal effect of chlorhexidine has been shown in many studies, and it has been 
demonstrated that exposure of C. albicans to chlorhexidine suppresses the   ability 
of candida to adhere to buccal epithelial cells. Immersion of acrylic dentures in chlo-
rhexidine suppresses adhesion of candida to the prosthesis.7 For these reasons, chlor-
hexidine may be considered as an appropriate alternative to conventional antimycotic 
drugs in the management of oral candidosis.8 It has been reported that the duration of 
inhibition of adherence of candida was longer-lasting when chlorhexidine was used 
rather than amphotericin B and nystatin.9
There are many oral delivery modes for chlorhexidine. It is used principally as a 
0.2% mouthwash with a topical mode of action. However, most of the agent is removed 
from the oral cavity during the first hour due to the diluent effect of saliva and the 
cleansing effect of the oral musculature, possibly reducing its therapeutic efficacy.10 
Biofilms of candida on mucosal and inert surfaces, such as dentures, may also   contribute Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to therapeutic failure by modifying the   susceptibility to 
antifungal agents.11 Poor patient compliance due to the need 
for frequent drug application and associated adverse effects 
could also result in recurrence of disease.12 A sustained-
release delivery system for treatment of denture stomatitis 
using chlorhexidine incorporated into a tissue conditioner has 
been investigated, and it has been confirmed that there was a 
gradual release of the drug from the tissue conditioner and 
inhibition of candida growth in vitro.13 A topical sustained-
release dosage form could help overcome the side effects of 
mouth rinsing with chlorhexidine and guarantee availability 
of the agent in the target area at a therapeutic   dosage. Such 
a dosage form of chlorhexidine would be able to release the 
drug at a low therapeutic level over a long period of time, 
and might thus prevent tooth staining and the bitter taste.14 
The emergence of chlorhexidine-resistant strains has not 
been observed clinically compared with the conventional 
antimycotic drugs, such as nystatin, amphotericin B, and 
recently mycostatin.15
Methods for detecting and estimating the eluates from 
poly (methyl methacrylate) (PMMA) acrylic denture bases 
have progressed over the past decades. The earlier methods 
were either physical or chemical in nature,16,17 but their poor 
detection limits rendered them unsuitable for detecting small 
amounts of leachate concentration. Therefore, these methods 
failed to provide an accurate estimation of leachates in acrylic 
resin bases. That was the situation until the advent of gas 
chromatography as a method of detecting residual mono-
mers and other leachates in acrylic resin bases.18 The ease of 
this technique has made the procedure suitable for clinical 
application. The technique has been used in the detection 
of residual monomer and other leachates in whole saliva of 
human subjects wearing acrylic palatal appliances.19,20
More recently, a novel method of acquiring the test speci-
men for investigation by gas chromatography was introduced,21 
whereby the eluates were extracted out of the polymerized 
acrylic resin plate using solvents. The resulting solution was 
then centrifuged, and the yield was subjected to gas chromato-
graphic analysis for estimation of eluate   concentrations. This 
method of investigation has been praised for its accuracy and 
precision,22,23 as well as detection sensitivity for extremely 
small amounts, ie, 1 ppm and less, of leachates.
The aim of the present investigation was to:
•	 Establish whether a chlorhexidine antifungal drug can be 
incorporated in a conventional autopolymerizing PMMA 
formulation
•	 Use the doped polymer for sustained intraoral delivery 
of chlorhexidine
•	 Investigate whether intraorally delivered chlorhexidine 
is of adequate concentration to have fungicidal activ-
ity against C. albicans and be a potential treatment for 
denture-induced oral candidiasis.
Materials and methods
sample preparation
A polymerized PMMA acrylic resin (Paladur®, Heraeus 
Kulzer, Wehrheim, Germany) at room temperature was used 
in this study. The mixing ratio and conditions for process-
ing and polymerization recommended by the manufacturer 
were followed strictly. The polymer powder/monomer liquid 
ratio for mixing was 5 g/3 mL. Two groups of disc-shaped 
PMMA specimens were prepared; samples for the first 
group were impregnated with chlorhexidine powder 10% 
w/w and samples for the second group (controls) were not 
(Figure 1).
Incorporation of chlorhexidine 10% w/w within the 
polymerized PMMA denture base polymer was indicated 
by mechanical tests carried out in a pilot study on the poly-
mer prior to the present investigation. The results of these 
tests indicated that chlorhexidine 10% was the maximum 
dose that could be safely incorporated in PMMA without 
having any undue effect on the mechanical properties of 
the polymer.
The antifungal drug was added in the specified ratio to 
the acrylic resin powder. The mixture of powders and liquid 
monomer was then stirred for 15 seconds and left standing 
for 4 minutes until a plastic dough was formed. The dough 
was then packed into a specially constructed disc-shaped 
steel mould to produce a disc specimen (3.8 mm diameter 
and 1.0 mm thickness). After packing, the mould was allowed 
to stand for 13 minutes, then placed in a pressure curing unit 
and cured at 55°C and 2 bar pressure for 15 minutes.
DRD containing CHX 10% PMMA control
Figure  1  Discs  of  the  two  specimen  groups  showing  the  drug  release  device 
(DRD) impregnated with chlorhexidine (ChX) 10% and the control poly (methyl 
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high performance liquid chromatography
Standard chlorhexidine was purchased from Cadilla 
Pharmaceuticals (Ahmad-Abad, India). The internal stan-
dard, p-methyl phenol, was purchased from Acros Organics 
(Geel, Belgium). The analysis was carried out on isocratic 
high-performance liquid chromatography apparatus consist-
ing of the following components: a high-performance liquid 
chromatography pump (LC 1110; GBC Scientific Equipment, 
Melbourne, Australia), a high-performance liquid chromatog-
raphy injector (Rheodyne 7125; PerkinElmer, Akron, OH), 
a high-performance liquid chromatography ultraviolet vis-
ible detector (LC 1205; GBC Scientific Equipment), and an 
integrator (LC 4290; Spectra Physics, Mountain View, CA). 
The high-performance liquid chromatography apparatus 
was operated under the following working conditions: 
acetonitrile/phosphate buffer 0.0 1M (25%:75%) eluent, an 
eluent flow rate 1.0 mL/min, injection volume 20 µL, a BDS-
C18 column (25 cm × 4.6 mm, particle size 5 µm), ultraviolet 
visible spectrophotometer ( λ 210 nm, range 1.0) detector, 
attenuation 8, and integrator chart speed 0.5 cm/minute.
standard stock and working solutions
A standard stock solution of 1000 µg/mL was prepared by 
dissolving 10 mg of the drug in 10.0 mL of high-performance 
liquid chromatography water. The solutions prepared were 
kept in a refrigerator. The standard working solution of 
chlorhexidine was prepared by mixing 20 µg/mL of the drug 
with 50 µg/mL of the p-methyl phenol internal standard in 
high-performance liquid chromatography water.
Leaching behavior
In the first group of samples, five discs, weighing 6.32 g each and 
containing chlorhexidine 10% w/w were each placed separately 
in a 10 mL screw-capped vial and then covered with 5 mL of 
double-distilled water. The vials were left in a water bath at 37°C 
with continuous gentle shaking. After 1 hour, 150 µL of aqueous 
solution of the corresponding internal standard (160 nmol/mL) 
was added and mixed. Finally, 20 µL of this mixture were 
injected onto the high-performance liquid chromatography 
column according to the abovementioned conditions. This 
procedure was repeated at 24 hours, at days 2, 3, 4, 5, 6, and 7, 
and every week for the next 4 weeks. The same procedure was 
repeated for the five blank PMMA control specimens.
Qualitative and quantitative analysis
A representative chromatogram of a standard mixture of 
chlorhexidine and the internal standard is shown in Figure 2. 
The qualitative identification of the drug peak was performed 
by comparing the relative retention time of the drug with 
respect to the internal standard in the real sample with that in 
the chromatogram for the standard drug mixture, which in this 
case was 4.860 minutes for chlorhexidine. The quantitative 
determination was performed using the relative peak areas 
and relative concentrations.
Microbiological investigation
A resistant strain of C. albicans was isolated from an inpatient 
at Jordan University Hospital and confirmed by biochemical 
tests. A reference strain of C. albicans (ATCC90028) was 
used as a control. Until testing, the yeasts were kept frozen 
in brain-heart broth (Difco Laboratories, Detroit, MI) with 
glycerol 5%. For each experiment, the strains were sub-
cultured twice on Saboraud agar (Difco Laboratories) for 
24 hours at 35°C to ensure viability and purity. The inoculum 
suspension was prepared by picking five colonies of at least 
1 mm in diameter and suspending them in 5 mL of sterile 
saline solution 0.85%.
Well diffusion test
The inoculum used was prepared using yeasts from a 24-hour 
culture on Saboraud agar, with a suspension made in sterile 
saline solution 0.85%. The turbidity of the suspension was 
adjusted using a spectrophotometer at 530 nm to obtain a 
final concentration matching that of a 0.5 McFarland standard 
(0.5–2.5 × 103). The inoculated agar was poured into the assay 
plate (9 cm in diameter) and allowed to cool down on a level 
surface. Once the medium had solidified, “wells” 4 mm in 
diameter were cut from the agar, and 20 µL of the chlor-
hexidine 10% eluates were placed into a well in separate 
assay plates. Control cups containing the drug-release device 
only were also included in each assay plate. The plates were 
incubated at 35°C for 72 hours.
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Figure 2 A representative chromatogram of a standard mixture of chlorhexidine 
with the internal standard.
Abbreviations: is, internal standard; ChX, chlorhexidine.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The absence of growth of C. albicans, demonstrated by 
the occurrence of a growth inhibition zone around the wells 
containing the chlorhexidine-impregnated drug-release 
device was interpreted as antifungal drug activity, which was 
expressed by measurement of the diameter of the inhibition 
zone present around the well accommodating the drug-release 
device, using a PBI Readbiotic (PBI International, Milano, 
Italy). Each experiment was carried out five times for the 
antifungal drug-impregnated release device and controls.
Results
Drug-release device
At the outset, incorporation of chlorhexidine into the polym-
erized PMMA acrylic resin at room temperature did not have 
any untoward effect on the polymerization reaction of PMMA 
or on preparation of the test sample.
Drug release
The antifungal drug, ie, chlorhexidine 10%, contained in 
the disc specimen demonstrated a high initial rate of elu-
tion from the PMMA drug-release reservoir during the first 
2–7 days, followed by a controlled sustained elution process 
that continued throughout the 28-day test period (Table 1 
and Figure 3). In general, chlorhexidine initially displayed a 
substantially high rate of release, reaching a concentration of 
up to 606 µg/mL, which was equivalent to 36.4 mg of drug 
released after 1 day. The rate of release thereafter became 
steadier until the end of the 28-day test period.
Microbiology
The percolate from the drug-release device containing chlor-
hexidine 10% showed clear antifungal activity. This was dem-
onstrated by comparing the zones of inhibition of C.   albicans 
growth around the wells containing the chlorhexidine-
impregnated drug-release device with those containing the 
drug-release device alone (Figure 4). Chlorhexidine   continued 
to demonstrate antifungal potential throughout the 28-day 
test period, as shown by the width of the inhibition zone of 
C. albicans growth vs time (Figure 5).
Discussion
The release of chlorhexidine from the PMMA drug-release 
device into distilled water indicates that polymerization of the 
PMMA acrylic resin did not adversely affect the antifungal 
drug nor did impregnation of the PMMA acrylic resin with 
chlorhexidine alter the diffusion characteristics of the resin. 
This finding is in agreement with that of previous studies 
using polymers for delivering chlorhexidine.24
The elution behavior of chlorhexidine from the autopo-
lymerized acrylic resin showed relatively high initial release 
into distilled water during the first 4 days, during which the 
diffusion gradient of chlorhexidine was significantly higher 
than that demonstrated during the rest of the 28-day exposure 
to distilled water at mouth temperature.
The change in the rate of drug release is attributed to the 
fact that leaching of chlorhexidine into water is governed 
by a concentration-dependent diffusion process.25 A similar 
elution profile was reported for residual unpolymerized 
methyl methacrylate monomer from the same autopolymer-
izing acrylic resin when exposed to both distilled water and 
artificial saliva at mouth temperature.26,27
The results of the present investigation highlight the 
remarkable release behavior of an antifungal drug, chlor-
hexidine 10% w/w, contained within a PMMA drug-release 
device. It has been clearly established that methacrylate-
based polymers absorb up to 30% water depending on the 
osmolarity of the external solution16 and the formulation of 
a particular polymer.24,25 The mechanism of elution seemed 
to consist of two phases, ie, rapid linear behavior obeying 
Fick’s law, followed by development of discrete clusters of 
the immersion liquid of unidentified osmotic activity.25
In the presence of chlorhexidine, the rapid elution phase 
indicates a surface release process. The subsequent slow sus-
tained release may be the result of complex processes, involv-
ing formation of fluid clusters around the drug molecules and 
the interaction of these clusters with the mechanism of fluid 
absorption of the acrylic resin. Similar behavior has been 
reported for the release of another drug from a methacrylate-
based polymeric system into distilled water.24 The elution 
behavior of chlorhexidine may also be enhanced by surface 
crazing and porosity, formed in the brittle PMMA by osmotic 
forces consequent to the inclusion of the antifungal drug. 
This is consistent with findings from a study using the same 
polymeric system for delivery of hydrocortisone.28
Table 1 Mean concentration (µg/mL) and amount (mg) values 
(n = 5) of the antifungal drugs released from the autopolymerized 
acrylic discs into distilled water at weekly intervals for the 28-day 
test period
Time (days) Drug release device with chlorhexidine 10%
Strength (μg/mL) Amount (mg)
1 606 36.4
7 803 48.2
14 885 53.1
21 946 56.8
28 974 58.4Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
223
new form of administering chlorhexidine
Having established that chlorhexidine-supplemented 
polymeric devices do release the antifungal drug in controlled 
concentrations for up to 4 weeks, it was essential to deter-
mine whether these concentrations were high enough to have 
antifungal activity against C. albicans, a common pathogen 
causing denture-induced stomatitis lesions. In this study, 
microbiological investigation showed that the antifungal drug 
was released at concentrations that did have an antifungal 
effect against C. albicans by inhibiting its growth in 
Saboraud culture for the 4-week test period. These findings 
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Figure 3 A plot of drug release concentration against time. The bottom part of the graph demonstrates the concentration of the released drug into distilled water daily. The 
immersion water was changed at every test interval. The top part of the graph demonstrates a hypothetical simulation of the clinical situation displaying what would be the 
cumulative concentration of chlorhexidine released at the denture/tissue interface and eventually absorbed by the tissues provided that the patient would wear the upper 
denture continually for 4 weeks. error bars represent the distribution of data around the mean value of three repeats.
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Figure 4 Zone of inhibition of Candida albicans growth around the well containing 
the drug release device (DRD) with 10% chlorhexidine (ChX). note the absence 
of  an  inhibition  zone  around  the  well  containing  the  control,  ie,  poly  (methyl 
methacrylate) alone.
0
37 14
Time (days)
M
e
a
n
 
i
n
h
i
b
i
t
i
o
n
 
z
o
n
e
 
w
i
d
t
h
 
(
m
m
)
21 28
10
20
30
40
50
60
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
CHK
Figure 5 A histogram plotting the width of the inhibition zones of candidal growth 
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are consistent with those of an earlier study29 showing that 
chlorhexidine diffuses out of an autopolymerized acrylic 
resin in effective fungicidal concentrations over a period of 
at least 3 weeks.
Our results indicate that a chlorhexidine-supplemented 
drug-release device has a powerful antifungal effect, demon-
strated by its capacity to inhibit growth of C. albicans. This 
interesting finding should encourage use of antifungal drugs 
in lower concentrations, thus reducing the chance of the host 
developing an allergic reaction to the drug, yet possessing a 
substantially high antifungal potential.
Future laboratory investigations could focus on studying 
the elution profile of chlorhexidine from an autopolymerized 
denture-based polymer into artificial saliva at different pH 
v  alues. Such investigations may yield findings more com-
parable with the clinical situation. In the clinical context, 
the cumulative nature of chlorhexidine release into the sur-
rounding fluid media helps saturate the salivary film, bathing 
the tissue surface of a denture base with continuous-release 
antifungal drug.
Conclusion
The findings of the present study show that the antifungal 
drug, chlorhexidine, can be successfully incorporated with 
autopolymerized PMMA, and that chlorhexidine leaches 
out of the polymer into the surrounding fluid medium in an 
environment similar to that in the oral cavity with respect to 
humidity and temperature. The sustained incremental elution 
of the antifungal drug from the impregnated-polymeric denture 
base maintains a gradually increasing concentration of the drug 
at the exact site where candidal infection lesions in the tissue 
bed of the maxillary denture are usually found. The results 
of the microbiological investigation in this study confirm the 
antifungal efficacy of the drug-supplemented delivery system 
and favor the use of polymeric systems doped with antifungal 
drugs in small concentrations. Clinical studies are essential in 
order to test the efficacy of the suggested drug delivery system, 
before implementing the new dosage form of antifungal drugs 
for the treatment of denture-associated oral candidiasis.
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